Meet the Experts begins at 12:00 PM. #IMS26

CAR-T in the outpatient setting➡️ Boisdale
Bispecifics in the outpatient setting ➡️ Dochart
Evaluating the immune system in multiple myeloma ➡️ Carron

At 12:00 PM in Alsh: Poster Discussion. #IMS26

Shaji Kumar, MD, synthesized current evidence to chart a pathway for improving myeloma care by leveraging blood-based technologies for detecting well-established and emerging/underexplored disease markers. #IMS26

Abstract Sessions begin at 11:00 AM. Join us in Hall 5 for Abstract Session 3 or Lomond Auditorium for Abstract Session 4. #IMS26

Starting at 11 a.m. BT at #IMS26 in Glasgow: Dr. Theresia Akhlaghi will present new findings that point to CD4-dominant, T-helper-skewed T cell state as a contributor to movement and neurocognitive toxicity after BCMA-directed CAR T therapy in multiple myeloma.

@mskcancercenter.bsky.social

Excited for day 2 at #IMS26!

Join us at 10:00 AM in Hall 5 as we celebrate excellence and honor this year's award recipients at the #IMS26 Awards Ceremony.

Read this Blood Cancer Discovery review by Editor-in-Chief Kenneth C. Anderson, “Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.” buff.ly/OLGKc5C #IMS26

Does every pt need BCMA or GPRC5d at first relapse? CAR-T, bispecific, or ADC? What abt tx sequencing? Patient preferences? Dr. Mateos used practical questions to frame the discussion on clinical decision-making at first relapse. #IMS26

Treatment at first relapse is largely driven by the target, with BCMA-directed options leading the field. Access to new therapies varies widely worldwide, however, and access barriers often dictate treatment choice. #IMS26

Dr. Krina Patel reviewed data supporting improved outcomes with earlier use of CAR-T, including at first relapse. Early CAR-T referral preserves more holding therapy options, she noted. #IMS26

At 8:30 AM in Hall 5: Blood-Based Technology for Diagnosis and Monitoring. #IMS26

Read this Blood Cancer Discovery review by #IMS26 speaker Ola Landgren, “Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.” buff.ly/R6x0mu8

Good morning and welcome to Day 2 of #IMS26. Join us for breakfast at 7:15 AM in Hall 5 during the Industry Symposium Supported by Pfizer, then explore today's educational sessions and events. View the program: https://ow.ly/hi6650ZQtxs

Don’t miss the IMS/AACR session on CAR T cells and the microbiome tomorrow at 2:30 PM, cochaired by Blood Cancer Discovery Editor-in-Chief Kenneth C. Anderson. #IMS26

Read the recently updated Myeloma Collection, showcasing impactful articles published in Blood Cancer Discovery: buff.ly/CnLyN2M #IMS26

Coming up at #IMS26: MSK myeloma specialist & cellular therapist Dr. Sham Mailankody will discuss bispecifics in the outpatient setting during a Meet the Experts session.

🗓️ Thursday, September 24 | 12 p.m. BT / 7 a.m. ET

Day 1 at #IMS26. New insights, meaningful discussions, and colleagues from around the world gathered in Glasgow.

Read this Blood Cancer Discovery research brief by #IMS26 speakers Nizar Bahlis, Holly Lee, Francesco Maura, and Leo Rasche, “Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies.” buff.ly/iE4saSy

Day 1 highlights from the 23rd IMS Annual Meeting! #IMS26